P art of the normal wound-healing process is the migration and proliferation of fibroblasts into the wound bed. In the wound bed, the fibroblasts will be involved in matrix deposition and remodeling by production of growth factors, cytokines, and receptors; production of matrix metalloproteinases and their inhibitors; as well as the synthesis of such extracellular matrix molecules as fibronectins, vitronectins, and collagens. All of these processes require precise regulation to reach optimal regeneration of the original tissue. Similarly, disturbance or malfunction of the process or one of the processes may lead to either excessive matrix production, such as in keloid and hypertrophic scar formation and in scleroderma, or to lack of wound closure, such as in diabetic foot ulcers. Whereas it has been known for quite some time that fibroblasts are involved in all these processes, it is only since recently that we have begun to understand that the origin and phenotype of the fibroblast are also important in determining the outcome of healing.
FIBROBLAST PHENOTYPES
One of the most well-known phenotypes of fibroblasts is the myofibroblast (Fig. 1 ). This cell type is usually identified by the presence of alpha-smooth muscle actin (a-SMA) and is thought to possess a higher contractile potential than "normal" fibroblasts, and its presence is commonly associated with fibrotic pathology such as lung or liver fibrosis, scleroderma, Dupuytren contracture, and so on. 1 Similar phenotypic differences between fibroblasts have been shown for cells originating from different tissues. Some examples of this are the following:
• Dermal versus subcutaneous fat-derived fibroblasts differ in contractile and proteolytic capacity. 2 • Oral mucosal as well as early gestational fetal tissue fibroblasts differ from dermal fibroblasts in the activity of tissue inhibitor of metalloproteases-1 and -2 (TIMP-1, TIMP-2), resulting in a lower level of active matrix metalloprotease-2 (MMP-2) in dermal fibroblasts. 3 • The expression of several receptor tyrosine kinases was elevated in fetal rat fibroblasts but not in adult fibroblasts. 4 Another difference between fetal and adult fibroblasts is the regulation of collagen production, which is higher in fetal than in adult cells. Whether these differences represent separate phenotypes or different characteristics from the same myofibroblast/fibroblast phenotypes is presently unknown.
Furthermore, phenotypic differences between fibroblasts from normal skin and pathological tissues have been demonstrated (among many others) in hypertrophic scars and keloids 5 and scleroderma, 6 all of which might bear some relation to the fibroblast-myofibroblast phenotypes. In diabetic ulcers, 7 a different fibroblast phenotype has been demonstrated, with a lowered level of cytoskeletal filaments, combined with a lower proliferation capacity. In fibroblasts isolated from adenocarcinoma tissue, gene expression profiles were compared to those of normal bronchus. 8 From the upand down-regulated gene patterns, it was concluded that phenotypically different fibroblast populations were present. It is not known if these different phenotypes are related to the myofibroblast phenotype.
Finally, phenotypic differences exist between fibroblasts within one type of tissue, derived from different locations such as dermal fibroblasts from nonglabrous (palms, soles) versus glabrous surfaces. 5 Proliferation in vitro of cells derived from palms and soles was faster, and the cells contained less a-SMA than normal skin fibroblasts. of a hypertrophic scar. Expression of such fibroblast phenotypes may occur, for example, in deep, fullthickness burn wounds. In those wounds, dermal tissue is fully destroyed, dermal fibroblasts are no longer present, and subcutaneous fat or even deeper layers of the tissue such as fascia, tendon, or bone may be exposed. Fibroblasts necessary for wound healing will be mainly recruited from the subcutaneous fat. As these cells express more a-SMA, they will react differently to stimuli from TGF beta and produce different levels of proteases and inhibitors, which will most likely result in the production of more extracellular matrix and the formation of a scar. Thus, the presence and activity of a nondermal fibroblast phenotype might be involved in the process of scar formation in full-thickness wounds.
In chronic wounds such as diabetic ulcers, we 7 and others 9 have demonstrated that fibroblasts isolated from such wounds have a reduced proliferative capacity and an altered response to growth factors 10 compared to both aged matched control fibroblasts and nonlesional fibroblasts from the same patient. The latter may have consequences for clinical wound-healing studies on the effects of growth factors or cytokines, as in many cases the preclinical studies to determine identity and concentrations of a growth factor to be used in the clinic are carried out using nonlesional or only aged matched cell populations. The clinical results may differ considerably from those of the laboratory studies, not only because the clinical/physiologi-cal or pathological conditions differ but also because the cellular response was tested on the wrong fibroblast phenotype.
THERAPEUTIC IMPLICATIONS
What can be learned from these findings? One obvious conclusion is that more detailed characterization of fibroblast phenotypes present in a particular situation is warranted. Such knowledge would enable the design of more customized therapeutic interventions at different levels.
In the concept of skin substitution, whether designed for treatment of chronic wounds, reconstructive wounds, or burn wounds, one has to take into account how the wound bed will react to the application of the substitute. The wound bed of a full-thickness burn will usually be surgically excised, exposing the subcutaneous fat layer. Frequently the wound cannot be transplanted with full skin but will be treated with a split thickness transplant, in some cases combined with a dermal substitute matrix. In those cases, the fibroblasts that will become active in the wound-healing process are generally derived from the subcutaneous fat, which possesses a less favorable phenotype to allow skin regeneration. Rather than regeneration, scar formation is bound to occur.
A much better result may be anticipated either by the application in a dermal substitute of fibroblasts with a dermal phenotype or by modulating the subcutaneous fat-derived cells in such a way that they would behave like fibroblasts with a dermal phenotype. Whereas treatment with TGF beta can induce the differentiation of fibroblasts into myofibroblasts, the tools to execute the reverse effectively are not yet available.
Margolis 11 stated that "in general, very few new experimental treatments for chronic wounds have performed as well in the clinical setting as in the preclinical lab setting." The incorrect test model (ie, the wrong fibroblast phenotype in preclinical testing) may have contributed to this poor performance. I can see an important task for scientific societies such as the European Tissue Repair Society, European Wound Management Association, and others, to improve scientific communication between clinicians, who are involved in the design of clinical trials, and basic scientists, who (may) have the cell biological knowledge to point out the pitfalls in these designs. Fig. 1 
